Drugs / GB-4362
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07484022 | Jun 2026 → Jun 2027 expected | urothelial carcinoma | Generate Biomedicines | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB-4362 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07484022 ↗ |
| Action | Inhibit | “GB-4362 is a monoclonal antibody designed to selectively bind and neutralize free MMAE in circulation” NCT07484022 ↗ |
| Modality | Monoclonal antibody | “GB-4362 is a monoclonal antibody” NCT07484022 ↗ |